Efficacy and safety of initial combination therapy with amlodipine/ valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: The EX-STAND study

Journal of Human Hypertension

Volumn 23, Issue 7, 2009, Pages 479-489

  Flack, J M ^a   Calhoun, D A ^b   Satlin, L ^c   Barbier, M ^c   Hilkert, R ^c   Brunel, P ^c  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Alabama at Birmingham   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS VALSARTAN; HYDROCHLOROTHIAZIDE; PLACEBO;

ADD ON THERAPY; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CHOLANGITIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FEMALE; HUMAN; HYPERTENSION; HYPOKALEMIA; INTERVERTEBRAL DISK HERNIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; NEGRO; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; THORAX PAIN; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; TETRAZOLES;

EID: 67649449128     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2008.153     Document Type: Article

References (33)

1. Ong KL, Cheung BMY, Man YB, Lau CP, Lam KSL. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007; 49: 69-75.
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al., the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
3. Douglas JG, Bakris GL, Epstein M, Ferdinand KC, Ferrario C, Flack JM et al. The Hypertension in African Americans Working Group. Management of high blood pressure in African Americans: Consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003; 163: 525-541.
4. Ferdinand KC, Saunders E. Hypertension-related morbidity and mortality in African Americans: Why we need to do better. J Clin Hypertens (Greenwich) 2006; 8(1 suppl 1): 21-30.
5. He J, Klag MJ, Appel LJ, Charleston J, Whelton PK. The renin-angiotensin system and blood pressure: Differences between blacks and whites. Am J Hypertens 1999; 12: 555-562.
6. Smith Jr SC, Clark LT, Cooper RS, Daniels SR, Kumanyika SK, Ofili E, et al., the American Heart Association Obesity, Metabolic Syndrome, and Hypertension Writing Group. Discovering the full spectrum of cardiovascular disease:RMinority Health Summit 2003: report of the Obesity, Metabolic Syndrome, and Hypertension Writing Group. Circulation 2005; 111: E134-e139.
7. Morris Jr RC, Sebastian A, Forman A, Tanaka M, Schmidlin O. Normotensive salt sensitivity: Effects of race and dietary potassium. Hypertension 1999; 33: 18-23.
8. Pratt JH. Central role for ENaC in development of hypertension. J Am Soc Nephrol 2005; 16: 3154-3159.
9. Price DA, Fisher ND. The renin-angiotensin system in blacks: Active, passive, or what? Curr Hypertens Rep 2003; 5: 225-230.
10. Hebert LA, Agarwal G, Ladson-Wofford SE, Reif M, Hiremath L, Carlton SG et al. Nocturnal blood pressure in treated hypertensive African Americans compared to treated hypertensive European Americans. J Am Soc Nephrol 1996; 7: 2130-2134.
11. Flack JM, Hamaty M. Difficult-to-treat hypertensive populations: Focus on African-Americans and people with type 2 diabetes. J Hypertens Suppl 1999; 17: S19-S24.
12. Hertz RP, Unger AN, Cornell JA, Saunders E. Racial disparities in hypertension prevalence, awareness, and management. Arch Intern Med 2005; 165: 2098-2104.
13. Giles T, Aranda Jr JM, Suh D-C, Choi I-S, Preblick R, Rocha R et al. Ethnic/racial variations in blood pressure awareness, treatment, and control. J Clin Hypertens (Greenwich) 2007; 9: 345-354.
14. Saunders E, Weir MR, Kong BW, Hollifield J, Gray J, Vertes V et al. A comparison of the efficacy and safety of a beta blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Mecd 1990; 150(8): 1707-1713.
15. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA 2002; 288: 2981-2997.
16. Nasser SA, Lai Z, O'Connor S, Liu X, Flack JM. Does earlier attainment of blood pressure goal translate into fewer cardiovascular events? Curr Hypertens Rep 2008; 10(5): 398-404.
17. Weir MR, Hall PS, Behrens MT, Flack JM. Salt and blood pressure responses to calcium antagonism in hypertensive patients. Hypertension 1997; 30(3): 422-427.
18. Brown NJ, Ray WA, Snowden M, Griffen MR. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 1996; 60(1): 8-13.
19. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF et al. Guidelines for management of hypertension: Report of the fourth working party of the British Hypertension Society, 2004 - BHS IV. J Hum Hypertens 2004; 18: 139-185.
20. Philipp T, Smith TR, Glazer R, Wernsing M, Yen J, Jin J et al. Two multicenter, 8-week, randomized, doubleblind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007; 29: 563-580.
21. Brachmann J, Ansari A, Mahla G, Handrock R, Klebs S. Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy. Adv Ther 2008; 25(5): 399-411.
22. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al., ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002; 4(6): 393-404.
23. Wright Jr JT, Douglas J. Optimal treatment of hypertension and cardiovascular risk reduction in African Americans: Treatment approaches for outpatients. J Clin Hypertens (Greenwich) 2003; 5(1 suppl 1): 18-25.
24. Flack JM, Ferdinand KC, Nasser SA. Epidemiology of hypertension and cardiovascular disease in African Americans. J Clin Hypertens (Greenwich) 2003; 5(1 Suppl 1): 5-11.
25. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99: 2434-2439.
26. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37: 1236-1241.
27. Hansen TW, Staessen JA, Torp-Pedersen C, Rasmussen S, Li Y, Dolan E et al. Ambulatory arterial stiffness index predicts stroke in a general population. J Hypertens 2006; 24: 2247-2253.
28. Blacher J, Staessen JA, Girerd X, Gasowski J, Thijs L, Liu L et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med 2000; 160: 1085-1089.
29. Murtaugh MA, Jacobs Jr DR, Yu X, Gross MD, Steffes M. Correlates of urinary albumin excretion in young adult blacks and whites: The Coronary Artery Risk Development in Young Adults Study. Am J Epidemiol 2003; 158: 676-686.
30. Flack JM, Duncan K, Ohmit SE, Quah R, Liu X, Ramappa P et al. Influence of albuminuria and glomerular filtration rate on blood pressure response to antihypertensive drug therapy. Vasc Health Risk Manag. 2007; 3(6): 1029-1037.
31. Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE, Crijns HJ, et al., for the Prevend Study Group. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001; 249: 519-526.
32. Jensen JS, Feldt-Rasmussen B, Borch-Johnsen K, Clausen P, Appleyard M, Jensen G. Microalbuminuria and its relation to cardiovascular disease and risk factors: A population-based study of 1254 hypertensive individuals. J Hum Hypertens 1997; 11: 727-732.
33. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH et al. RENAAL study investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.